Comparative Pharmacology
Head-to-head clinical analysis: FACTREL versus LEUPROLIDE ACETATE FOR DEPOT SUSPENSION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTREL versus LEUPROLIDE ACETATE FOR DEPOT SUSPENSION.
FACTREL vs LEUPROLIDE ACETATE FOR DEPOT SUSPENSION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist; stimulates pituitary release of LH and FSH initially, then suppresses gonadotropin secretion after chronic administration due to receptor downregulation.
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Continuous administration suppresses pituitary gonadotropin secretion, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby reducing gonadal steroid production (testosterone and estrogen).
100 mcg subcutaneously or 100 mcg intravenously, single dose for pituitary stimulation testing.
3.75 mg IM every 4 weeks or 11.25 mg IM every 12 weeks for advanced prostate cancer; 3.75 mg IM every month for endometriosis or uterine leiomyomas; 7.5 mg IM monthly for central precocious puberty.
None Documented
None Documented
Terminal elimination half-life is approximately 30-45 minutes. Short half-life necessitates continuous or repeated administration for sustained therapeutic effect.
3-4 hours for subcutaneous injection; after depot injection, initial burst release followed by slow release with apparent half-life of approximately 3-4 weeks due to absorption rate-limited elimination.
Primarily renal (95% as unchanged drug and metabolites). Fecal excretion accounts for <5%.
Primarily renal (metabolites), approximately 5% unchanged; fecal elimination accounts for <5%.
Category C
Category D/X
GnRH Agonist
GnRH Agonist